Zentera Therapeutics’ $75 Million Series B Financing

Wilson Sonsini Goodrich & Rosati advised Tybourne Capital Management on the deal.

Zentera Therapeutics, a clinical-stage biopharmaceutical company, completed a $75 million Series B financing. Founding investors OrbiMed Advisors Asia and Tybourne Capital Management led the financing.

Shanghai, China-based Zentera Therapeutics was formed by Zentalis Pharmaceuticals Inc. to develop cancer therapies in China. Zentera plans to use the proceeds of the financing to advance the clinical development of three of Zentalis’ product candidates, and to expand its pipeline through additional business development opportunities for China and global development.

The Wilson Sonsini team advising Tybourne Capital Management includes partner Dan Koeppen (Picture) and associate Meghan Burton.

 

Involved fees earner: Meghan Burton – Wilson Sonsini Goodrich & Rosati; Dan Koeppen – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Tybourne capital management;

Author: Martina Bellini